Evidence map›Paper›PMID 37524110›Full record

Trial reportExperimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association2023

Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD.

Lin Liu, Ruwen Wang, Jian Gao, Jianhua Yan, Jingtian Zhang, Zhitian Zhang, Jiaojiao Liu, Huandong Lin, Shengxiang Rao, Xiuzhong Yao and 6 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02303730 (Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02303730 phase4completednot on this map

Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes

TypeinterventionalSponsorFudan UniversityRan2015 to 2017Enrolled76ConditionsDiabetes Mellitus, Type 2, Non-alcoholic Fatty Liver DiseaseArmsExenatide, insulin glargine
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Effects of GLP-1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD: A Systematic Review.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Lin Liu *Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Ruwen Wang *School of Kinesiology, Shanghai University of Sport, Shanghai, China.
Jian Gao *Department of Nutrition, Zhongshan Hospital, Fudan University.
Jianhua YanShanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Jingtian ZhangDepartment of Nutrition, Zhongshan Hospital, Fudan University.
Zhitian ZhangDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Jiaojiao LiuDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Huandong LinDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Shengxiang RaoDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiuzhong YaoDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Weiyun WuDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Hua BianDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiangyu WangDepartment of Nutrition, Zhongshan Hospital, Fudan University.
Shanshan GuoSchool of Kinesiology, Shanghai University of Sport, Shanghai, China.
Xin GaoDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Hongmei YanDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Fudan University · CNSun Yat-sen University · CNZhongshan Hospital · CNShanghai University of Sport · CNThe First Affiliated Hospital, Sun Yat-sen University · CNShanghai University of Medicine and Health Sciences · CN

Funding

Medical Guidance Project of Shanghai Science and Technology Commission 19401931100 to Wang XYScience and Technology Commission of Shanghai Municipality 21ZR1413200 to HM YanScientific Research and Development Foundation of Zhongshan Hospital, Fudan University 2019ZSFZ10 to HD LIN
6 · The paper itself

Abstract

aimThis study investigated the effects of insulin glargine and exenatide on the muscle mass of patients with newly diagnosed type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).

methodsWe performed a post-hoc analysis of our previously study, a 24-week randomized controlled multicenter clinical trial (ClinicalTrials.gov, NCT02303730). Seventy-six patients were randomly assigned 1:1 to receive insulin glargine or exenatide treatment. The changes in psoas muscle area (PMA) (mm

resultsThere were no significant differences in age, BMI, gender, and PMA in insulin glargine and exenatide groups at baseline. After treatment, PMA tended to increase by 13.13 (-215.52, 280.80) mm

conclusionCompared to exenatide, insulin glargine can relativity increase PMA in patients with T2DM having BMI<28 kg/m

Indexed as

Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseCross-Sectional StudiesExenatideFemaleHumansHypoglycemic AgentsInsulin GlargineMaleMusclesVenomsExenatideHypoglycemic AgentsInsulin GlargineVenoms

Identifiers

PMID37524110
PMCPMC10645484
OpenAlexW4385411679

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.